News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Deals
France’s NicOx SA to Buy Back Eye Drug Rights from Pfizer Inc. (JOBS)
August 6, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- French biotech firm NicOx (NCOX.PA) will buy back the rights to develop and market a drug that seeks to treat eye disease glaucoma from U.S. drugmaker Pfizer (PFE.N) and said it was open to finding another partner.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
Europe
Pfizer
MORE ON THIS TOPIC
Tariffs
Biotech’s Next Phase Will Be All-American: Pitchbook
April 17, 2025
·
2 min read
·
Annalee Armstrong
Artificial intelligence
Sanofi Bets More Than $1.8 Billion in Biobucks on AI-Developed Bispecifics
April 17, 2025
·
2 min read
·
Dan Samorodnitsky
Mergers & acquisitions
Bluebird’s Second Suitor, Ayrmid, Fails To Produce an Offer
April 16, 2025
·
1 min read
·
Dan Samorodnitsky
Europe
With Tariffs Looming, EU and US Pharmas Make Demands of European Commission
April 16, 2025
·
2 min read
·
Tristan Manalac